ConductScience.org, home

Comparison · NCT03809429-531115ca

FE 999049 + GnRH Agonist (GONAPEPTYL) vs FE 999049 + GnRH Antagonist (CETROTIDE): Proportion of Subjects With Late OHSS (Including OHSS of Moderate/Severe Grade)

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. FE 999049 + GnRH Agonist (GONAPEPTYL) vs FE 999049 + GnRH Antagonist (CETROTIDE): Proportion of Subjects With Late OHSS (Including OHSS of Moderate/Severe Grade). Trial comparisons, record NCT03809429-531115ca. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03809429-531115ca

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.01980.007730.0498wilson
Risk in group 20.02940.01350.0627wilson
Risk difference, group 1 minus group 2-0.00961-0.0450.0243newcombe hybrid score
Risk ratio, group 1 over group 20.6730.1932.35log
Odds ratio, group 1 over group 20.6670.1852.4log
Number needed to treat, for one fewer participant with the outcome on FE 999049 + GnRH Agonist (GONAPEPTYL) than on FE 999049 + GnRH Antagonist (CETROTIDE)104from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1FE 999049 + GnRH Agonist (GONAPEPTYL)FE 999049 + GnRH agonist (GONAPEPTYL): Pre-filled injection pen4202OG000
Group 2FE 999049 + GnRH Antagonist (CETROTIDE)FE 999049 + GnRH antagonist (CETROTIDE): Powder and solvent for solution for injection6204OG001

Outcome

Type
SECONDARY
Title
Proportion of Subjects With Late OHSS (Including OHSS of Moderate/Severe Grade)
Description
Classification of grade was according to Golan's classification system, and all OHSS cases were graded as mild, moderate or severe.
Time frame
>9 days after triggering of final follicular maturation
Population
Participants analyzed for this endpoint represent participants who were evaluable for this outcome measure.

Source ClinicalTrials.gov

Trial

Title
Follitropin Delta in Long GnRH Agonist and GnRH Antagonist Protocols (BEYOND)
NCT number
NCT03809429
Phases
PHASE3
Conditions
Infertility, Female
Interventions
FE 999049 + GnRH agonist (GONAPEPTYL), FE 999049 + GnRH antagonist (CETROTIDE)
Lead sponsor
Ferring Pharmaceuticals
Results first posted
2024-05-13

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03809429-531115ca